<?xml version="1.0" encoding="UTF-8"?>
<p>Fiore et al. contribute to the issue [
 <xref rid="B5-antibiotics-10-00141" ref-type="bibr">5</xref>] with a systematic evaluation of the effectiveness of the ceftazidimeâ€“avibactam (CZA) combination, which was recently approved for the treatment of severe infections. The authors performed a systematic review and network meta-analysis (NMA) with the aim of comparing the effectiveness of CZA monotherapy versus combination therapy with other antibiotics in terms of mortality in patients with carbapenemase-producing Enterobacteriaceae (CRE) infections.
</p>
